Cite
HARVARD Citation
Pritchard-Jones, K. et al. (2015). Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 386 (9999), pp. 1156-1164. [Online].